Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176933
Title: | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) |
Author: | Gonzalez Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer Palter, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera Álvarez, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura, 1953- Martínez Picado, Francisco Javier Cerezuela, Pablo Soria, Ainara Marquez, Ivan Mandala, Mario Berrocal, Alfonso Spanish Melanoma Group (GEM). |
Keywords: | Melanoma Immunoteràpia Càncer Melanoma Immunotheraphy Cancer |
Issue Date: | Mar-2021 |
Publisher: | BMJ Publishing Group |
Abstract: | Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. |
Note: | Reproducció del document publicat a: https://doi.org/10.1136/jitc-2020-001664 |
It is part of: | Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 3, p. e001664 |
URI: | http://hdl.handle.net/2445/176933 |
Related resource: | https://doi.org/10.1136/jitc-2020-001664 |
ISSN: | 2051-1426 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
711684.pdf | 2.36 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License